NSAID Labeling Revisions Revised Again In Response To Industry Comments
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised template for OTC nonsteroidal anti-inflammatory drugs drops the “longer than 10 days” use timeframe in the cardiovascular risk warning in exchange for “long term continuous use.” New supplemental labeling request restarts six-month clock for firms to revise labeling.
You may also be interested in...
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Chattem’s Financing Strategy Keeps Door Open For Acquisitions
Chattem remains in the hunt for acquisitions because its preferred financing strategy continues to be attractive even with lending activity slowed worldwide, according to President and Chief Operating Officer Bob Bosworth